The GLP-1 Receptor Agonist Market is estimated to be valued at US$ 14319.85 Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:
GLP-1 receptor agonists are a class of drugs used for glycemic control in patients with type 2 diabetes. They are injectable drugs that mimic the effects of the natural hormone glucagon-like peptide-1 (GLP-1). By binding to GLP-1 receptors, they stimulate insulin secretion, suppress glucagon secretion, slow gastric emptying and enhance satiety. Compared to other diabetes drugs, they provide better glycemic control with a lower risk of hypoglycemia and do not result in weight gain.

Market key trends:
Once-weekly dosing - Manufacturers are developing once-weekly formulations of GLP-1 receptor agonists to improve patient adherence. Drugs such as semaglutide (Ozempic) and exenatide (Bydureon BCise) only require weekly administration. This long-acting profile makes therapy more convenient.
Combination therapies - Companies are exploring fixed-dose combinations of GLP-1 receptor agonists with other anti-diabetic drugs. For instance, the fixed combination of insulin degludec and liraglutide (Xultophy) was approved by the FDA in 2016. Such combinations provide enhanced glycemic control through complementary mechanisms of action.

Porter’s Analysis
Threat of new entrants: GLP-1 receptor agonist market requires substantial R&D investment and regulatory approvals posing high entry barriers.
Bargaining power of buyers: Presence of large pharmaceutical buyers allows them to negotiate on price however growing patient demand limits their influence.
Bargaining power of suppliers: Pharmaceutical ingredient suppliers hold some bargaining power due to specialized technical expertise required.
Threat of new substitutes: New lines of oral and non-injectable substitutes pose threats by offering better therapy adherence.
Competitive rivalry: Intense competition exists among global established players to gain higher market share through continuous product innovations.

SWOT Analysis
Strengths: High efficacy in glycemic control and weight loss benefits leading to patient preference over other antidiabetic classes.
Weaknesses: Inconvenient modes of administration via injections and high costs limiting access in price sensitive regions.
Opportunities: Large underserved diabetes population worldwide, favorable regulatory approvals for new line extensions and novel delivery formulations.
Threats: Patent expiries of leading brands, pricing pressures from payers, stringent regulatory norms for approvals.

Key Takeaways
The Global GLP-1 Receptor Agonist Market Size is expected to witness high growth, exhibiting CAGR of 6.1% over the forecast period, due to increasing prevalence of diabetes globally. Approvals of new line extensions along with novel oral formulations will also support market growth.

Regional analysis: North America dominates the GLP-1 receptor agonist market currently owing to established healthcare systems and early approvals of innovative drugs. Asia Pacific is emerging as the fastest growing regional market due to rising diabetes burden, healthcare reforms and expanding access.

Key players operating in the GLP-1 receptor agonist market are Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.

Read more: https://www.trendingwebwire.com/glp-1-receptor-agonist-market-share-analysis/